.

Thank you for the detailed report. Based on the transcripts, the key financial metrics for Global Human Health in 2016 include:

1. Annual sales of $35.2 billion, representing a 2% growth.
2. Fourth quarter sales of $8.9 billion, with a 1% decline.
3. Sales of KEYTRUDA reaching $1.4 billion for the full year, with $482 million in the fourth quarter.
4. JANUVIA franchise generating sales of $6.1 billion with 4% growth globally and 12% growth in the U.S.
5. Vaccine business sales growing 10% to $6.2 billion for the full year, with GARDASIL sales increasing 14%.
6. Hospital and specialty care sales of $8.1 billion for the full year, with a 2% growth.

The report also highlights the impact of LOEs on revenue and the company's commitment to building leadership positions for KEYTRUDA, JANUVIA, and vaccines. Additionally, the potential impact of KEYNOTE-021G on non-squamous lung market and the company's confidence in the I-O/I-O combinations are discussed as potential growth drivers for the future.